Ifebemtinib FA NEW
| Price | $98 | $248 | $413 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Ifebemtinib FA | Purity: 99.75% |
| Supply Ability: 10g | Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Ifebemtinib FA |
| Description | Ifebemtinib FA (BI-853520 FA) is an orally active and potent inhibitor of adhesion patch kinase (FAK) with anticancer and antiproliferative activity for the study of ovarian and lung cancer. |
| In vitro | The compound Ifebemtinib FA (BI-853520 FA) inhibits cancer cell growth at concentrations ranging from 0 to 3 μM for 2 hours[2]. Repression of tumor cell proliferation and invasion in 3D culture is observed with Ifebemtinib FA at concentrations from 0 to 30 μM for 4-6 days[1]. Additionally, Ifebemtinib FA represses Y397-FAK autophosphorylation at concentrations ranging from 0 to 10 μM for 24 hours, and at a concentration of 0.1 μM for 96 hours, Ifebemtinib FA demonstrates a fast and potent inhibition of FAK in this highly metastatic murine breast cancer cell line[3]. |
| In vivo | The oral gavage treatment of Ifebemtinib FA (BI-853520 FA) at a dose of 50 mg/kg once daily for 0-8 weeks significantly suppresses the primary tumor growth of all three cell lines in vivo[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | FAK | BI853520FA(1227948824Freebase) |
| Inhibitors Related | Chloropyramine hydrochloride | FAK-IN-15 | FAK-IN-14 | (R)-Fangchinoline | Roslin 2 bromide | APG-2449 | Ifebemtinib | OXA-11 | Creosol | Y15 | PND-1186 | FAK-IN-10 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $997.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
|
VIP3Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2026-03-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY